SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pa...
SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Since the ‘cell-cyclerelated’ cluster already encompasses a standard regimen drug, cytarabine, we focused on other pathways (Figures 2A–D and S2–S4; Table 1). For the proteomics database, we leveraged Gene Set Variation Analysis (GSVA), originally used for transcriptomic data, to generate pathway scores. MTHFD2 gene expression exhibited a significa...
Alternative Titles
Full title
SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_cd99b2717b584580ace5eb7d6677a706
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cd99b2717b584580ace5eb7d6677a706
Other Identifiers
ISSN
2001-1326
E-ISSN
2001-1326
DOI
10.1002/ctm2.1311
